U.S. Comparative Effectiveness Will Not Copy U.K.’s NICE – OMB Director
This article was originally published in The Tan Sheet
Executive Summary
The Obama administration is not looking to build a government entity charged with making cost-effectiveness decisions when reviewing the clinical effectiveness of medical treatments, according to Office of Management and Budget Director Peter Orszag
You may also be interested in...
Comparative Effectiveness Could Take A Close Look At CAM - Sebelius
Comparative effectiveness research required under health care reform likely will be used to carefully test the value of complementary and alternative medicines rather than simply hold up those products as less-expensive alternatives to pharmaceuticals
Comparative Effectiveness Could Take A Close Look At CAM - Sebelius
Comparative effectiveness research required under health care reform likely will be used to carefully test the value of complementary and alternative medicines rather than simply hold up those products as less-expensive alternatives to pharmaceuticals
Comparative Effectiveness Could Take A Close Look At CAM - Sebelius
Comparative effectiveness research required under health care reform likely will be used to carefully test the value of complementary and alternative medicines rather than simply hold up those products as less-expensive alternatives to pharmaceuticals